Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERA therapy for Alport syndrome on background RAAS blockade
ChiCTR2500107030Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Alport syndrome comparing ERA group (ambrisentan) with Placebo group (2 arms). Primary endpoint: 24-hour urinary protein excretion. Started Aug 2025; status: recruiting.
02
Drugs
ambrisentan
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on ChiCTR2500107030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107030.